Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Mol Divers ; 22(2): 335-342, 2018 May.
Artigo em Inglês | MEDLINE | ID: mdl-29302847

RESUMO

The aim of this work is to introduce, model, and optimize a new non-acid-catalyzed system for a direct N[Formula: see text]N-C bond formation. By reacting naphthols or phenol with anilines in the presence of the sodium nitrite as nitrosonium ([Formula: see text] source and triethylammonium acetate (TEAA), a N[Formula: see text]N-C group can be formed in non-acid media. Modeling and optimization of the reaction conditions were investigated by response surface method. Sodium nitrite, TEAA, and water were chosen as variables, and reaction yield was also monitored. Analysis of variance indicates that a second-order polynomial model with F value of 35.7, a P value of 0.0001, and regression coefficient of 0.93 is able to predict the response. Based on the model, the optimum process conditions were introduced as 2.2 mmol sodium nitrite, 2.2 mL of TEAA, and 0.5 mL [Formula: see text] at room temperature. A quadratic (second-order) polynomial model, by analysis of variance, was able to predict the response for a direct N=N-C group formation. Predicted response values were in good agreement with the experimental values. Electrochemistry studies were done to introduce new Michael acceptor moieties. Broad scope, high yields, short reaction time, and mild conditions are some advantages of the presented method.


Assuntos
Nitrito de Sódio/química , Acetatos/química , Compostos de Anilina/química , Catálise , Química Verde , Temperatura
2.
Int J Biol Macromol ; 125: 785-790, 2019 Mar 15.
Artigo em Inglês | MEDLINE | ID: mdl-30543880

RESUMO

Chitosan-based hydrogel nanoparticles provide a higher brain concentration of methotrexate (MTX) following IV administration in comparison with the drug's simple solution. The present study investigates the mechanism of this phenomenon, focusing on the possible role of P-gp. A previously developed MTX containing chitosan nanogel was fabricated and characterised. Then 48 rats were divided into four groups: two receiving nanogels and two receiving solution of MTX, while 1 of each two had received a verapamil dose 30 min before MTX. Then, rats were sacrificed in four time points in triplicate, and MTX concentration in their plasma and brains were quantified and were compared statistically. Following IV injection, spherical nanogels with a mean diameter of <200 nm, zeta potential of 22.8 ±â€¯6.55 mv, Loading efficiency of 72.03 ±â€¯0.85, and loading capacity of 1.41 ±â€¯0.02 produce a significantly higher brain concentration compared with the simple solution. Furthermore, those receiving verapamil presented a higher brain concentration. It seems that in the short term after drug administration (<1 h) nanogels facilitate MTX passage by providing a higher concentration of drug in contact with BBB, but in a more extended period nanogels pass the BBB and release their content beyond that.


Assuntos
Encéfalo/efeitos dos fármacos , Quitosana/química , Hidrogéis/química , Metotrexato/administração & dosagem , Metotrexato/química , Nanopartículas/química , Animais , Portadores de Fármacos/química , Sistemas de Liberação de Medicamentos/métodos , Tamanho da Partícula , Ratos , Verapamil/administração & dosagem , Verapamil/química
3.
Int Urol Nephrol ; 51(12): 2235-2242, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-31641998

RESUMO

Hyperlipidemia and oxidative stress are indispensable features of chronic kidney disease (CKD) that favor the development of atherogenic plaques and cardiovascular disease (CVD). A number of vasoactive mediators including proprotein convertase subtilisin-kexin type 9 (PCSK9), endothelin-1, nitric oxide, and angiotensin II have fundamental roles in the pathophysiology of atherosclerotic events; moreover, their levels are affected by dyslipidemia and oxidative stress due to renal dysfunction. Therefore, therapeutic measures aimed at correcting dyslipidemia and alleviating oxidative stress could potentially protect against CVD in CKD patients. In this review, we discuss the relation between dyslipidemia, oxidative stress, and vasoactive mediators as well as the available treatment options against these disturbances in CKD patients.


Assuntos
Angiotensina II/fisiologia , Dislipidemias/complicações , Dislipidemias/metabolismo , Endotelina-1/fisiologia , Óxido Nítrico/fisiologia , Estresse Oxidativo , Pró-Proteína Convertase 9/fisiologia , Insuficiência Renal Crônica/complicações , Insuficiência Renal Crônica/metabolismo , Humanos
4.
Iran J Basic Med Sci ; 22(2): 179-186, 2019 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-30834084

RESUMO

OBJECTIVES: Cisplatin is an effective antineoplastic agent; its clinical utility, however, is limited by a few salient toxic side effects like nephrotoxicity. This study aimed to determine the potential protective effects of tangeretin, a citrus-derived flavonoid, against renal tubular cell injury in cisplatin-induced renal toxicity of rats. MATERIALS AND METHODS: Tangeretin was injected intraperitoneally at 2.5 and 5 mg/kg doses for 10 days, and a single dose of cisplatin (8 mg/kg) was injected on the 7th day. Tests of kidney function and tubular injury in renal tissues and urine together with oxidative stress and inflammation markers were examined. RESULTS: Tangeretin ameliorated cisplatin-induced elevations in serum creatinine, BUN, and histopathologic changes. It also attenuated kidney oxidative stress elicited by cisplatin as demonstrated by reduced MDA and increased GSH, CAT, and SOD activities, elevated Nrf2 expression and protein levels of its downstream effectors, HO-1 and NQO-1. Tangeretin further alleviated inflammation evoked by cisplatin as indicated by reduced NF-κB p65 subunit phosphorylation with a simultaneous decrement in its downstream effectors IL-1ß and TNF-α expression and protein levels. Moreover, it declined caspase-3 protein levels and TUNEL positive cells in the kidneys, the markers of apoptosis and DNA fragmentation, thus improving renal endurance. Additionally, tangeretin mitigated renal levels of KIM-1 and NGAL, as well as urinary cystatin C and ß2-microglobulin concentrations, the markers of renal tubular injury. CONCLUSION: Collectively, these data signify the binary profit of tangeretin: enhancement of renal protective mechanisms against cisplatin and attenuation of renal tubular cell injuries induced by the agent.

5.
Transpl Immunol ; 57: 101241, 2019 12.
Artigo em Inglês | MEDLINE | ID: mdl-31446153

RESUMO

BACKGROUND: One of the important factors in the occurrence of acute kidney injury (AKI) among renal transplant patients (RTPs) is ischemia reperfusion injury (IRI). The current study aimed at determining the anti-inflammatory and anti-oxidative effects of melatonin on the complications of IRI and the level of Klotho expression in these patients. METHODS: A total of 40 renal transplant candidates were randomly assigned into placebo or melatonin group receiving the same dose of 3 mg/day. In order to measure serum melatonin levels, inflammatory and oxidative stress factors, renal function biomarkers, and Klotho gene/protein expression, venous blood samples were taken from patients over two different time points, i e, 24 h before the transplantation and at discharge from hospital. RESULTS: Melatonin was associated with improvement in renal transplantation, since the serum level of neutrophil gelatinase-associated lipocalin, as a renal functional marker, significantly decreased (P < .001). The effect of melatonin as a suppressor of inflammation and oxidative stress was also evident in the melatonin group due to a significant reduction in the serum levels of MDA, CP, 8-OHdG, and TNF-α markers (P < .001). CONCLUSIONS: Reduction in serum levels of renal function and oxidative stress/inflammatory markers in the melatonin group indicates that melatonin can inhibit IRI outcomes in RTPs through its anti-oxidant and anti-inflammatory properties. However, these properties do not appear as a result of influence on the level of Klotho gene/protein expression.


Assuntos
Anti-Inflamatórios/uso terapêutico , Antioxidantes/uso terapêutico , Glucuronidase/metabolismo , Transplante de Rim , Melatonina/uso terapêutico , Traumatismo por Reperfusão/prevenção & controle , 8-Hidroxi-2'-Desoxiguanosina/sangue , Adulto , Método Duplo-Cego , Feminino , Regulação da Expressão Gênica/efeitos dos fármacos , Glucuronidase/genética , Humanos , Proteínas Klotho , Lipocalina-2/sangue , Masculino , Malondialdeído/sangue , Pessoa de Meia-Idade , Carbonilação Proteica , Fator de Necrose Tumoral alfa/sangue
6.
Clin Biochem ; 55: 3-8, 2018 May.
Artigo em Inglês | MEDLINE | ID: mdl-29608890

RESUMO

Post-transplant ischemic acute kidney injury (AKI), secondary to ischemia reperfusion injury (IRI), is a major problem influencing on the short and long term graft and patient survival. Many molecular and cellular modifications are observed during IRI, for example, tissue damage result production of reactive oxygen species (ROS), cytokines, chemokines, and leukocytes recruitment which are activated by NF-κB (nuclear factor kappa B) signaling pathway. Therefore, inhibiting these processes can significantly protect renal parenchyma from tissue damage. Klotho protein, mainly produced in distal convoluted tubules (DCT), is an anti-senescence protein. There is increasing evidence to confirm a relationship between Klotho levels and renal allograft function. Many studies have also demonstrated that expression of the Klotho gene would be down regulated with IRI, so it will be used as an early biomarker for acute kidney injury after renal transplantation. Other studies suggest that Klotho may have a renoprotective effect for attenuating of kidney injury. In this review, we will discuss pathophysiology of IRI-induced acute kidney injury and its relation with klotho level in renal transplantation procedure.


Assuntos
Injúria Renal Aguda/metabolismo , Glucuronidase/metabolismo , Transplante de Rim , Traumatismo por Reperfusão/metabolismo , Transdução de Sinais , Injúria Renal Aguda/etiologia , Injúria Renal Aguda/patologia , Aloenxertos , Animais , Citocinas/metabolismo , Humanos , Proteínas Klotho , NF-kappa B/metabolismo , Espécies Reativas de Oxigênio/metabolismo , Traumatismo por Reperfusão/patologia
7.
J Physiol Biochem ; 74(3): 467-478, 2018 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-29948786

RESUMO

Despite the effectiveness of renin-angiotensin blockade in retarding diabetic nephropathy progression, a considerable number of patients still develop end-stage renal disease. The present investigation aims to evaluate the protective potential of FPS-ZM1, a selective inhibitor of receptor for advanced glycation end products (RAGE), alone and in combination with valsartan, an angiotensin receptor blocker, against glomerular injury parameters in streptozotocin-induced diabetic rats. FPS-ZM1 at 1 mg/kg (i.p.), valsartan at 100 mg/kg (p.o.), and their combination were administered for 4 weeks, starting 2 months after diabetes induction in rats. Tests for kidney function, glomerular filtration barrier, and podocyte slit diaphragm integrities were performed. Combined FPS-ZM1/valsartan attenuated diabetes-induced elevations in renal levels of RAGE and phosphorylated NF-κB p65 subunit. It ameliorated glomerular injury due to diabetes by increasing glomerular nephrin and synaptopodin expressions, mitigating renal integrin-linked kinase (ILK) levels, and lowering urinary albumin, collagen type IV, and podocin excretions. FPS-ZM1 also improved renal function as demonstrated by decreasing levels of serum cystatin C. Additionally, the combination also alleviated indices of renal inflammation as revealed by decreased renal monocyte chemoattractant protein 1 (MCP-1) and chemokine (C-X-C motif) ligand 12 (CXCL12) expressions, F4/80-positive macrophages, glomerular TUNEL-positive cells, and urinary alpha-1-acid glycoprotein (AGP) levels. These findings underline the benefits of FPS-ZM1 added to valsartan in alleviating renal glomerular injury evoked by diabetes in streptozotocin rats and suggest FPS-ZM1 as a new potential adjunct to the conventional renin-angiotensin blockade.


Assuntos
Benzamidas/uso terapêutico , Diabetes Mellitus Experimental/complicações , Nefropatias Diabéticas/prevenção & controle , Barreira de Filtração Glomerular/efeitos dos fármacos , Receptor para Produtos Finais de Glicação Avançada/antagonistas & inibidores , Insuficiência Renal/prevenção & controle , Valsartana/uso terapêutico , Administração Oral , Bloqueadores do Receptor Tipo 1 de Angiotensina II/administração & dosagem , Bloqueadores do Receptor Tipo 1 de Angiotensina II/uso terapêutico , Animais , Benzamidas/administração & dosagem , Biomarcadores/sangue , Biomarcadores/metabolismo , Biomarcadores/urina , Nefropatias Diabéticas/metabolismo , Nefropatias Diabéticas/patologia , Nefropatias Diabéticas/fisiopatologia , Quimioterapia Combinada , Barreira de Filtração Glomerular/metabolismo , Barreira de Filtração Glomerular/patologia , Barreira de Filtração Glomerular/fisiopatologia , Injeções Intraperitoneais , Macrófagos/efeitos dos fármacos , Macrófagos/imunologia , Macrófagos/patologia , Masculino , Microscopia de Fluorescência , Fosforilação/efeitos dos fármacos , Podócitos/efeitos dos fármacos , Podócitos/imunologia , Podócitos/metabolismo , Podócitos/patologia , Processamento de Proteína Pós-Traducional/efeitos dos fármacos , Distribuição Aleatória , Ratos Wistar , Receptor para Produtos Finais de Glicação Avançada/metabolismo , Insuficiência Renal/complicações , Insuficiência Renal/metabolismo , Insuficiência Renal/fisiopatologia , Fator de Transcrição RelA/metabolismo , Valsartana/administração & dosagem
8.
Free Radic Res ; 52(7): 808-817, 2018 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-29865885

RESUMO

Despite being an efficacious anticancer agent, the clinical utility of cisplatin is hindered by its cardinal side effects. This investigation aimed to appraise potential protective impact of dunnione, a natural naphthoquinone pigment with established NQO1 stimulatory effects, on cisplatin nephrotoxicity of rats. Dunnione was administered orally at 10 and 20 mg/kg doses for 4 d and a single injection of cisplatin was delivered at the second day. Renal histopathology, inflammatory/oxidative stress/apoptotic markers, kidney function, and urinary markers of renal injury were assessed. Dunnione repressed cisplatin-induced inflammation in the kidneys as indicated by decreased TNF-α/IL-1ß levels, and reduced nuclear phosphorylated NF-κB p65. This agent also obviated cisplatin-invoked oxidative stress as elucidated by decreased MDA/GSH levels and increased SOD/CAT activities. Dunnione, furthermore, improved renal histological deteriorations as well as caspase-3 activities and terminal deoxynucleotidyl transferase (TUNEL) positive cells, the indicators of apoptosis. Moreover, it up-regulated nuclear Nrf2 and cytosolic haeme-oxygenase-1 (HO-1) and NQO1 levels; meanwhile, promoted NAD+/NADH ratios followed by enhancing the activities of Sirt1 and PARP1; and further attenuated nuclear acetylated NF-κB p65. Dunnione additionally declined cisplatin-evoked retrogression in renal function and upraise in urinary markers of glomerular and tubular injury as demonstrated by decreased serum urea and creatinine with simultaneous reductions in urinary excretions of collagen type IV, podocin, cystatin C, and retinol-binding protein (RBP). Altogether, these findings offer dunnione as a potential protective agent against cisplatin-induced nephrotoxicity in rats.


Assuntos
Cisplatino/toxicidade , Regulação da Expressão Gênica/efeitos dos fármacos , Nefropatias/prevenção & controle , NAD(P)H Desidrogenase (Quinona)/metabolismo , NAD/metabolismo , Naftoquinonas/farmacologia , Substâncias Protetoras/farmacologia , Animais , Antineoplásicos/toxicidade , Apoptose/efeitos dos fármacos , Inflamação/prevenção & controle , Nefropatias/induzido quimicamente , Nefropatias/metabolismo , NAD(P)H Desidrogenase (Quinona)/genética , Estresse Oxidativo/efeitos dos fármacos , Ratos , Ratos Wistar
9.
Eur J Med Chem ; 45(12): 5979-84, 2010 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-21035921

RESUMO

A series of dibenzyl-γ-butyrolactones bearing a hydroxyl group at the benzylic position of 3-benzyl group were synthesized as hydrated analogue of isochaihulactone and evaluated against breast cancer human cell lines (MDA-M231, MCF-7 and T47D). The target compounds were synthesized in 7 steps from known lactone; (S)-(+)-γ-benzyloxymethyl-γ-butyrolactone. The key step was the aldol condensation between (+)-(R)-ß-(benzo[d][1,3]dioxol-5-ylmethyl)-γ-butyrolactone and substituted benzaldehydes which afforded corresponding α-hydroxybenzyl butyrolactone analogues. The cytotoxic study of the synthesized compounds against breast cancer human cell lines showed that some of them inhibit breast cancer human cell proliferation with percentage inhibitions over 50% at concentrations less than 50 µg/mL.


Assuntos
4-Butirolactona/análogos & derivados , Antituberculosos/farmacologia , Benzodioxóis/farmacologia , 4-Butirolactona/síntese química , 4-Butirolactona/química , 4-Butirolactona/farmacologia , Antituberculosos/síntese química , Antituberculosos/química , Benzodioxóis/síntese química , Benzodioxóis/química , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Ensaios de Seleção de Medicamentos Antitumorais , Humanos , Estrutura Molecular , Estereoisomerismo , Relação Estrutura-Atividade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA